Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 12/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29807685 | 1.00 | PRKCI (0.46) | PRKCICYP2A6LPLLIPGIRAK4 | |
| SCHEMBL31500017 | 0.89 | LPL (0.39) | PRKCICYP2A6LPLLIPGIRAK4 | |
| SCHEMBL2215446 | 0.87 | IRAK4 (0.46) | PRKCICYP2A6LPLLIPGIRAK4 | |
| SCHEMBL29894116 | 0.87 | IRAK4 (0.46) | PRKCICYP2A6LPLLIPGIRAK4 | |
| SCHEMBL31500583 | 0.81 | LPL (0.40) | LPLLIPGIRAK4CA1CA2 | |
| SCHEMBL17673204 | 0.81 | LPL (0.40) | LPLLIPGIRAK4CA1CA2 | |
| SCHEMBL14790351 | 0.81 | LPL (0.44) | LPLLIPGIRAK4 | |
| SCHEMBL2383644 | 0.80 | LPL (0.43) | LPLLIPGIRAK4 | |
| SCHEMBL16322931 | 0.80 | LPL (0.38) | LPLLIPGIRAK4 | |
| SCHEMBL16651441 | 0.79 | IDO1 (0.40) | LPLLIPGIRAK4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740948-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND | Dong Wha Pharm. Co., Ltd. (KR) | 2026-05-13 | — | — | EP | disclosed |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2025-02-20 | — | — | US | disclosed |
| EP-4464701-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| CN-116444479-B | Preparation method of high optical purity L-lactide | 扬州大学 | 2024-08-02 | — | — | CN | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| WO-2010011964-A2 | IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | PRKCI 1765/4885CYP2A6 787/4885LPL 3805/4885 |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CYP2C9, CYP1B1, SULT1A1 | PRKCI 4825/4885CYP2A6 87/4885LPL 2984/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | PRKCI 340/4885CYP2A6 3411/4885LPL 4579/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | PRKCI 444/4885CYP2A6 4620/4885LPL 2371/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | PRKCI 444/4885CYP2A6 4620/4885LPL 2371/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | PRKCI 340/4885CYP2A6 3411/4885LPL 4579/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | PRKCI 340/4885CYP2A6 3411/4885LPL 4579/4885 |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | PRKCI 3860/4885CYP2A6 1821/4885LPL 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.